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Abstract 
In Chronic Myeloid Leukemia (CML), standard treatment consists of modern tyrosine-kinase 
inhibitors (TKI). Nevertheless, there is evidence that immune responses against leukemia-
associated antigens (LAA) may play an important role in disease control. Dendritic cell (DC)- 
based immunotherapy is able to induce T cell responses against LAA and might therefore 
pose an interesting therapeutic option in CML, especially in the setting of minimal residual 
disease (MRD). GMP production of DC for clinical vaccination remains a time- and cost- 
intensive procedure and standardized DC generation is warranted. We asked whether 
maturation-induction with IFN-γ and IFN-α has an influence on functional properties of DC 
derived from peripheral blood mononuclear cells (PBMC) in CML patients. Monocyte-derived 
DC from healthy donors and from patients with CML were analyzed after maturation-
induction with our TNF-α-containing standard cytokine cocktail with or without addition of 
IFN-α and/or IFN-γ. Our results confirm that the addition of IFN-γ leads to enhanced IL-12 
secretion in healthy donors. In contrast, in CML patients, IFN-γ was not able to increase IL-12 
secretion, possibly due to a higher degree of cell adherence and lower cell yield during the 
cell culture. Our data suggest, that- in contrast to healthy donors-, additional interferons are 
not beneficial for maturation induction during large-scale DC production in patients with CML.  
 
Introduction 
Chronic myeloid leukemia is a clonal myeloproliferative disorder in which the characteristic 
reciprocal translocation, t(9;22)(q34;q11) forms the Philadelphia chromosome and leads to 
the fusion gene BCR-ABL.1 In CML, the predominant gene product of this reciprocal 
translocation is the BCR/ABL fusion protein p210, which shows abnormal tyrosine-kinase 
activity that is crucial for the pathogenesis of the disease. 2, 3 The introduction of tyrosine 
kinase inhibitors (TKI) has revolutionized CML treatment and has become a paradigm of 
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“targeted therapy” since the late 1990ies. 4, 5  TKI treatment with Imatinib and in particular the 
second generation TKI Nilotinib and Dasatinib has substantially increased the proportion of 
patients achieving deep molecular responses. This improvement of the quality of remission 
has translated into a substantially longer progression-free and promising overall survival. 5  
However, most CML patients– despite achieving deep molecular remissions- remain 
BCR/ABL-positive, suggesting disease persistence at least at a very low level. In this 
situation of minimal residual disease (MRD) on a molecular level, additional 
immunotherapeutic strategies such as interferon therapy or vaccination against leukemia- 
associated antigens seems particularly promising with regard to a possible eradication of 
residual leukemia cells. In fact, there is a large body of evidence showing that CML is an 
“immunoresponsive” disease: 1) interferon therapy is able to induce complete cytogenetic 
responses in up to 30% of CML patients; 6 2) induction of T cell responses against 
proteinase-3 correlates with ongoing remissions under interferon therapy and after allogeneic 
stem cell transplantation (SCT); 7 3) donor lymphocyte infusions (DLI) are able to induce 
long-lasting remissions in relapsed CML patients after allogeneic SCT 8 and 4) immune 
responses against CML-specific and CML-associated antigens such as BCR/ABL, 
proteinase-3 and WT-1 can be detected in CML patients and vaccination is able to enhance 
these immunological responses and can also induce clinical responses in some CML 
patients. 9-19 Untreated CML patients show severe immunosuppression caused by multiple 
mechanisms: induction of myeloid-derived suppressor cells, regulatory T cells, secretion of 
soluble factors such as VEGF, PIGF and TGF-ß and the expression of immunosuppressive 
molecules such as PD-1 or NOX/NOX2. Additionally, function and maturation of dendritic 
cells may be impaired. 20-24 Therefore, the deep molecular responses observed under TKI 
therapy may also reverse immunosuppression that is induced by a large tumor burden. DC 
are key regulators of MHC-restricted T cell responses in humans and are considered as 
“nature´s adjuvant”. 25  The feasibility of DC- based immunization strategies in CML patients 
has been demonstrated by several groups including ours, although most of these studies 
were performed in CML patients, who had not achieved a major molecular remission. 15, 26-29 
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Ex- vivo generation and maturation of DC is a crucial step for these strategies and different 
cytokine cocktails have been described which are mainly based on GM-CSF, IL-4 and TNF-
α. 15, 16, 30-32 Kalinski et al. reported that interferons are able to induce DC that combine 
several important features with regard to their TH1-polarizing capacity: mature phenotype, 
responsiveness to secondary lymphoid organ chemokines and high IL-12 producing ability. 
33, 34 Therefore, the aim of our present study was to assess the influence of interferons during 
ex vivo DC generation on the functional properties of DC in CML patients. 15 
 
Results 
DC generation in healthy donors and CML patients: influence of interferons on 
phenotype and cell yield 
After 8 days of cell culture, peripheral blood monocytes had acquired a typical DC 
morphology. Viability was always > 80%. The immunophenotype of DC at the end of the 
culture was consistent with mature DC showing lineage- negative cells with high expression 
of CD80, CD83, CD86, and HLA- DR. 15, 16 The addition of IFN-γ (or IFN-γ plus IFN-α in CML 
patients) did not significantly affect the TNF-α− induced mature phenotype as measured by 
flow cytometry (data not shown). However, cell culture in CML patients revealed substantially 
more cell adherence after addition of interferon-γ (Figure 1a-c).   In fact, addition of IFN-γ led 
to 7.1% adherent cells in the cell culture as compared to 0.9% without IFN-γ. However, this 
effect of IFN-γ on cell adherence was reversed when IFN-α was added (adherent cells 0.8%) 
(data not shown). The influence of interferons on DC yield in CML patients after 8 days of cell 
culture was even more pronounced: mean DC yield without interferons was 105 667 cells per 
cm2, whereas it decreased to 59 133 per cm2 (only 50% of the cell yield with TNF-α alone) 
after addition of IFN-γ during maturation induction. Possibly due to the small number of 
patients, this difference was not statistically significant (p=0.2). Combined use of IFN-γ and 
IFN-α was not able to reverse this negative impact on DC yield (DC with IFN-γ and IFN-α: 54 
333 per cm2) (Figure 1d). 
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Influence of interferons on the cytokine secretion profile of DC after CD40 ligation in 
healthy donors 
TH1-polarizing capacity of DC from healthy donors as measured by IL-12 secretion was 
studied by using xenogeneic CD40L-transfected 3T3 cells in order to mimic DC-T cell-
interactions. 3T3 WT cells served as control. In DC from healthy donors, inclusion of IFN-γ 
into the maturation cocktail indeed led to an increase of IL-12 secretion after CD40-ligation 
by 3T3-CD40L cells (mean IL-12 secretion without IFN versus IFN-γ: 765 vs. 1924 pg/ml, 
p=0.043, Figure 2a). However, there was also an increase of IL-10 production resulting in an 
overall unchanged or even decreased ratio of IL-12 to IL-10 (mean IL-10 secretion without 
IFN versus IFN-γ: 192 vs. 540 pg/ml, p=0.068; IL-12/IL-10 ratio without IFN versus IFN-γ: 3.3 
vs. 2.6, Figure 2b-c). The production of IL-6 and IL-8 was not changed (data not shown).  
Cytokine secretion profile of DC after CD40 ligation in chronic phase CML patients: 
influence of interferons  
Subsequently, the influence of IFN-γ was also studied in DC from chronic phase BCR/ABL+ 
CML patients. At the end of the cell culture, DC were stimulated by xenogeneic, CD40L-
transfected 3T3 cells. The cytokine profile was measured thereafter. Surprisingly, IL-12-
production was not increased after the addition of IFN-γ. On the contrary, a tendency towards 
lower IL-12-production was observed (mean IL-12 secretion without IFN versus IFN-γ: 136.6 
vs. 73.8 pg/ml, p= 0.055, Figure 3a) when IFN-γ was added into the DC culture. Since 
combined use of IFN−γ and IFN-α has been previously reported to increase IL-12 secretion 
in DC from healthy donors, we also used a combination of IFN-γ and IFN-α in our DC 
cultures from CML patients to exclude that these results were caused by a lack of IFN-α 
during the DC culture. However, even the combined use of IFN-γ and IFN-α was not able to 
consistently increase IL-12 production of CML-DC after CD40-ligation (mean IL-12 in pg/ml: 
without IFN: 136.6; with IFN-γ 73,8; with IFN-γ plus IFN-α: 130 (Figure 3a). Additionally, IL-10 
production was also observed to be lower after addition of IFN-γ into the DC culture (mean 
IL-10 in pg/ml: without IFN: 433.5; with IFN-γ: 170.6; with IFN-γ plus IFN-α: 280.5, Figure 3b).  
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With regard to production of IL-4, the cytokine profile remained largely unchanged after 
addition of interferons and CD40 ligation (data not shown).  
T cell stimulatory capacity of DC in chronic phase CML patients: Influence of 
interferons  
To assess the T cell stimulatory capacity of DC matured under these different conditions in 
patients with chronic phase CML, an allogeneic MLR was used: In line with our previous 
results regarding the cytokine profile, no increase of the stimulatory ability of CML-DC was 
observed after addition of IFN-γ or IFN-γ plus IFN-α during cell culture (mean CPM of cells 
after maturation-induction without IFN: 27342 + 712; with IFN-γ: 24029 + 727; with IFN-γ plus 
IFN-α: 24005 +168), Figure 3c).   
 
Discussion 
IL-12 secretion by DC is a very helpful surrogate parameter for the TH1-polarizing capacity of 
in vitro generated DC. 35 Previous reports in healthy individuals have described multiple 
different cytokine cocktails for maturation induction in DC. IL-12 production was commonly 
used as a measure for the TH1-polarizing capacity. IL-1ß/TNF-α and IFN-γ are amongst the 
cytokines which have been used for ex vivo DC generation. 33, 36 Subsequently, it was 
demonstrated that combined use of IFN-γ and IFN-α was able to induce a mature DC 
phenotype with superior IL-12 production in DC from healthy individuals. 34, 37 During the 
interaction of DC with T cells, CD40- ligation is a crucial step leading to IL-12 production and 
consequently TH1-polarized T cells. 35, 38 Additionally, it has recently been shown, that CD40 
ligation leads to “reticulation” of DC, promoting intercellular transfer between DC with 
consecutive improved antigen-presenting capacity. 39 Therefore, our approach was to mimic 
CD40-CD40L interaction by CD40L-transfected 3T3 cells and thus establish an in vitro 
method to quantify the TH1-polarizing capacity of in vitro generated DC by IL-12 production 
after CD40-ligation. 
In this study, we show that – in contrast to DC from healthy individuals- interferons are not 
sufficiently able to increase the TH1-polarizing capacity of DC from CML patients as 
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compared to our maturation protocol including TNF-α alone. Since phenotype and cytokine 
profiles of DC have been extensively characterized 40, our study focused on IL-12- and IL-10-
production, which is assumed to reflect the ability of in vitro generated DC to induce TH1 
polarization. Therefore, we used IL-12/IL-10 ratios as a measure for the TH1- polarizing 
capacity of DC. 32 Essentially we asked whether IL-12 production can be increased by IFN-α 
and/or IFN-γ in DC from CML patients in chronic phase. Our results with DC from healthy 
donors generated in the presence of IFN-γ confirm that IL-12 production can be increased by 
IFN-γ after CD40 ligation, however, this effect was not observed with DC from chronic phase 
CML patients, neither with IFN-γ alone nor with a combination of IFN-γ and IFN-α. Since 
enhancement of IL-12 secretion was only observed with CD40L-transfected cells and not 
with 3T3 wild type cells, we were able to exclude that the effect is simply mediated by 
xenoreactivity. In line with the cytokine profile observed after maturation in the presence of 
interferons (with an overall unchanged IL-12/IL-10 ratio), an improvement of the T cell 
stimulatory capacity by interferons was not observed. Regarding possible causes for these 
results, an increased cell adherence during cell culture and a substantially reduced DC yield 
were the most prominent findings after addition of interferons into the maturation cocktail. 
Increased cell adherence has previously been described to impair DC maturation and 
cytokine secretion. 32 However, in our case this would neither explain the difference between 
healthy donors and CML patients nor the substantial reduction of the DC yield that was 
observed after inclusion of interferons into the maturation cocktail. Therefore, it has to be 
assumed that – besides inducing a higher cell adherence - interferons also reduce the 
percentage of surviving cells during DC culture. While increased cell adherence was a 
common feature both in DC from healthy donors and from CML patients, the lack of IL-12 
production upon maturation in the presence of interferons was only found in DC from CML 
patients and thus seems to be CML-related. CML-related features leading to this difference 
might be: 1) direct cytotoxic effects of interferons on “leukemic” (= BCR/ABL+) PBMC and/or 
“leukemic” DC. This seems at least very likely since interferons were the standard of care for 
a long period; 41-44 2) an impairment of DC function itself which has been previously reported; 
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24 or 3) a treatment-related functional impairment in DC from CML patients since DC were 
generated from patients under therapy with tyrosine kinase inhibitors. Impaired immune 
responses have been described under TKI therapy by several groups. 45  
Interestingly, Bocchia et al. reported on possible synergistic effects of IFN-α and a BCR/ABL 
multipeptide vaccine in a small observational study. 46 This is not necessarily in contrast to 
our observation, since 1) the effects of IFN-α on (leukemic) DC during in vitro culture may not 
reflect the situation in vivo and 2) additional immunostimulatory effects of IFN-α on 
immunological effector cells such as T cells are well established.  
In conclusion, our results are in line with previous publications showing that functional DC 
can be generated ex vivo in CML patients, both in the chronic phase of the disease (giving 
rise to BCR/ABL+ “leukemic” DC) and in cytogenetic/molecular remission. 15, 26, 47-49 With 
regard to an interferon-induced “DC1 phenotype” that has been previously described 
(reviewed in 40), we could confirm higher IL-12 secretion in DC from healthy donors as 
compared to our standard cocktail containing GM-CSF, IL-4 and TNF-α alone. However, this 
interferon-induced increase in IL-12 production could not be found in DC from CML patients.  
Due to higher cell adherence and a lower DC yield observed after the use of interferons, we 
currently do not recommend their use under the culture conditions used in our GMP facility. 
Immunotherapeutic perspectives in CML in the MRD setting under TKI therapy include 
vaccination strategies with DC + additional immune checkpoint inhibitors. Consequently, 
improved large- scale DC generation from CML patients is clearly needed.  Therefore, 
refined protocols for DC generation, which address the challenges of cell adherence/ cell 
yield and - at the same time - support an appropriate DC1- phenotype, are warranted. 
 
Material and Methods 
Generation of DC from PBMCs 
DC were generated from eight healthy donors and three patients with chronic phase 
BCR/ABL+ CML as previously described and in accordance with local ethical guidelines. 15, 
16, 26 PBMCs were enriched by density gradient centrifugation on Lymphoprep (Nycomed 
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Pharma, Oslo, Norway) and then stored on liquid nitrogen in 42.5% human serum albumin 
(HSA, 20% solution, Octapharma, Langenfeld, Germany), 10% DMSO (Sigma, St. Louis, 
USA), and 47.5% RPMI (BioWhittaker, Walkersville, USA). Thawing of PBMCs was 
performed by the addition of HBSS w/o Ca++/Mg++ (BioWhittaker) containing 5% HSA. 
PBMCs were washed twice and then exposed to plastic adherence for monocytic 
enrichment. Briefly, PBMCs were seeded at a density of 1.4 -1.6 x106 cells/cm2 in 75 –cm2 
culture flasks (Corning Incorporated, Nagog Park, Acton, MA), and allowed to adhere for 1.5 
h at 37 °C in RPMI 1640 containing 5% HSA and 1% sodium pyruvate (BioWhittaker). Non-
adherent cells were removed by washing four times. Adherent cells were cultured in RPMI 
1640 supplemented with100 ng GM-CSF (Essex Pharma GmbH, Munich, Germany), 1000 
U/ml clinical grade IL-4 (kindly provided by Essex Pharma), 10% FCS and 1% sodium 
pyruvate for 5 days. As the standard procedure, 50 ng/ml clinical grade TNF-α (Boehringer 
Ingelheim, Ingelheim, Germany) was added to the culture medium on day 5 for another 3-4 
days.  
To assess the influence of interferons, IFN-γ or IFN-γ plus IFN-α (Strathmann Biotec AG, 
Hamburg, Germany) was added at a concentration of 1000 U/ml during the last 3-4 days of 
the cell culture. DC were then stimulated with 3T3 wild type cells or 3T3 cells that had been 
transfected with human CD40L (3T3-CD40L) for 24 - 48 hours.  Xenogeneic transfected and 
non-transfected 3T3 cells were kindly provided by C.A. Schmitt, Berlin. On days 8-9, DC 
were harvested and washed three times and were then frozen and stored on liquid nitrogen 
as previously described. 16 The phenotype of DC was characterized by flow cytometry as 
previously described. 15 The purity of the DC culture was always > 70%, T cell contamination 
was <10%. 
Proliferation assays 
Proliferation assays were performed as previously described. 50 Briefly, allogeneic PBMCs 
were used as responder cells. Triplicates of 105 PBMCs per well were cultured in RPMI 1640 
medium supplemented with 4 mM L-Glutamine, 25 mM HEPES (Lonza, Verviers, Belgium) 
and 10-15 % heat-inactivated FCS (HyClone, Thermo Fisher Scientific, Utah, USA), further 
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referred to as complete medium. 105 DC cultured with our standard cytokine cocktail with or 
without additional IFN-α or IFN-α plus IFN-γ were used as stimulator cells. After radiation 
with 30Gy (irradiation source: 137Cs, OB29, STS, Braunschweig, Germany), proliferative 
capacity of the responder cells was measured in a standard 4- day 3H-thymidine proliferation 
assay. During the last 16 h of the 4 days culture, 1 mCi/ml 3H-thymidine (Amersham Life 
Science, Buckingham, UK) was added. Cells were harvested and radioactivity measured in a 
scintillation counter. Maximum proliferation rate was determined by cultivation of 105 PBMCs 
in the presence of PHA. Minimum proliferation rate was determined by cultivation of PBMCs 
alone. Mean values were calculated. 	  
Detection of cytokine secretion in the culture supernatant 
The cytokine secretion in the culture supernatant was measured by Cytometric bead array 
(CBA) or ELISA. The cytokine pattern measured by the CBAs used in this study (Becton 
Dickinson, Franklin Lakes, NJ, USA) consisted of IFN-γ, TNF-α, IL-4, IL-6, IL-8, and IL-10. 
CBA were performed as previously described. 50 Briefly, 105 PBMCs were stimulated for 4 
days with 10 5 xenogeneic 3T3 WT - or 3T3-CD40L-transfected cells. Culture supernatant 
was frozen at -20°C until cytokine analysis was performed according to the manufacturers 
instructions. IL-12p70 production in the cell culture supernatant was assessed by ELISA on a 
VersaMax microplate reader (Molecular Devices, Biberach, Germany) and analyzed by 
Softmax Pro software 6.2.2. All other cytokines were assessed by CBA and analyzed on a 
FACS Navios (Beckman Coulter, Pasadena, CA, USA) by FCAP-Software (Soft Flow 
Hungary Ltd., Pecs, Hungary).  
Statistical analysis 
Statistical analysis was done descriptively. The differences in parameters between two 
subsets (without IFN versus with IFN-γ and without IFN versus with IFN-γ plus IFN-α) were 
calculated and the Wilcoxon test was applied in order to determine statistical significance. 
Differences with p values < 0.05 were considered to be statistically significant. Analyses were 
done by means of SPSS software (version 22). 
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Figure Legends 
 
Figure 1. Cell adherence and cell yield of DC from CML patients after 
maturation induction with IFN-γ   
Using our standard cytokine cocktail, DC generation from PBMC of CML patients and 
healthy individuals gives comparable results (a and b). In contrast, addition of 
interferons leads to an increase of cell adherence and a lower DC yield (c and d). 
a: DC culture from a healthy donor, b: DC culture from a patient with CML in chronic 
phase cultured with our standard cytokine cocktail (GM-CSF, IL-4, TNF-α) without 
interferons, c: Increased DC adherence in a DC culture containing IFN-γ in a chronic 
phase CML patient, d: Decreased DC yield (in cells per cm2) in cell cultures from 
CML patients containing IFN- γ or IFN-γ + IFN-α.  
*=Difference (as compared to “no IFN”) not statistically significant (p=0.2), possibly 
due to high variation in a low number of samples (no IFN: n=3, IFN-γ: n=3, IFN-γ + 
IFN-α: n=3).  
 
Figure 2.  Influence of IFN-γ  on the cytokine secretion profile of DC after CD40 
ligation in healthy donors   
DC from healthy donors were generated under different maturation conditions 
(standard cytokine cocktail without vs. with IFN-γ). The cytokine profile was 
measured by CBA (or ELISA for IL-12) after CD40 ligation.  
a: IL-12 secretion into the culture supernatant without vs. with IFN-γ (p=0.043),  
b: IL-10 secretion into the culture supernatant without vs. with IFN-γ (p=0.068), 
c: IL-12/IL-10 ratio without vs. with IFN-γ. 
HD= healthy donor 
**=p<0.05 as compared to “no IFN”; *=p= not significant as compared to “no IFN”.  
 
Figure 3. Influence of IFN-γ  on the cytokine secretion profile of DC after CD40 
ligation in chronic phase CML patients.  
a: IL-12 secretion of DC from patients with CML after maturation-induction with our 
standard cytokine cocktail without vs. with interferons (without IFN vs. IFN-γ: 
p=0.055; without IFN vs. IFN-γ plus IFN-α: p=0.91), 
b: IL-10 secretion of DC from patients with CML after maturation-induction with our 
standard cytokine cocktail without vs. with interferons (without IFN vs. IFN-γ: p=0.28; 
without IFN vs. IFN-γ plus IFN-α: p=0.9), 
c: T cell stimulatory capacity of DC generated with our standard cytokine cocktail 
without interferons as measured by a 3H-thymidine proliferation assay (mean CPM of 
cells after maturation-induction without IFN: 27342 + 712; with IFN-γ: 24029 + 727); 
with IFN-γ plus IFN-α: 24005 +168).    
IL-12 was determined by ELISA, all other cytokines by CBA. 
*= not statistically significant 
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